CN108354938A - Janus激酶（jak）抑制剂的给药方案 - Google Patents

Janus激酶（jak）抑制剂的给药方案 Download PDF

Info

Publication number: CN108354938A
Authority: CN; China
Prior art keywords: therapeutically effective; atopic dermatitis; dose; administration; effective dose
Prior art date: 2012-07-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN201810369706.3A

Other languages

English (en)

Chinese (zh)

Inventor

A·J·冈萨雷斯

S·B·科斯格罗夫

P·B·马尔帕斯

M·R·斯特格曼

W·T·科勒德

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Zoetis LLC

Zoetis Services LLC

Original Assignee

Zoetis LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-07-20

Filing date

2013-07-18

Publication date

2018-08-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48901189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN108354938(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-07-18 Application filed by Zoetis LLC filed Critical Zoetis LLC

2018-08-03 Publication of CN108354938A publication Critical patent/CN108354938A/zh

Status Pending legal-status Critical Current

Links

239000003112 inhibitor Substances 0.000 title claims abstract description 7
102000015617 Janus Kinases Human genes 0.000 title abstract description 13
108010024121 Janus Kinases Proteins 0.000 title abstract description 13
201000008937 atopic dermatitis Diseases 0.000 claims abstract description 48
206010012438 Dermatitis atopic Diseases 0.000 claims abstract description 44
238000011282 treatment Methods 0.000 claims abstract description 30
208000024891 symptom Diseases 0.000 claims abstract description 15
241000282472 Canis lupus familiaris Species 0.000 claims description 51
208000003251 Pruritus Diseases 0.000 claims description 32
239000003814 drug Substances 0.000 claims description 18
150000003839 salts Chemical class 0.000 claims description 12
230000037396 body weight Effects 0.000 claims description 11
HJWLJNBZVZDLAQ-UHFFFAOYSA-N n-methyl-1-[4-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexyl]methanesulfonamide Chemical compound C1CC(CS(=O)(=O)NC)CCC1N(C)C1=NC=NC2=C1C=CN2 HJWLJNBZVZDLAQ-UHFFFAOYSA-N 0.000 claims description 9
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 8
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical group OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 7
229940116839 Janus kinase 1 inhibitor Drugs 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 3
206010003645 Atopy Diseases 0.000 claims 1
241000124008 Mammalia Species 0.000 abstract description 31
229940122245 Janus kinase inhibitor Drugs 0.000 abstract description 21
238000000034 method Methods 0.000 abstract description 21
208000010668 atopic eczema Diseases 0.000 abstract description 7
230000009467 reduction Effects 0.000 abstract description 7
206010012434 Dermatitis allergic Diseases 0.000 abstract description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 32
201000010099 disease Diseases 0.000 description 31
229940125904 compound 1 Drugs 0.000 description 29
241001465754 Metazoa Species 0.000 description 28
150000001875 compounds Chemical class 0.000 description 23
102000004127 Cytokines Human genes 0.000 description 20
108090000695 Cytokines Proteins 0.000 description 20
229940079593 drug Drugs 0.000 description 14
230000007803 itching Effects 0.000 description 14
239000000902 placebo Substances 0.000 description 10
229940068196 placebo Drugs 0.000 description 10
230000000694 effects Effects 0.000 description 9
230000005764 inhibitory process Effects 0.000 description 9
201000004624 Dermatitis Diseases 0.000 description 8
VQIGDTLRBSNOBV-VQIYXBGXSA-N chembl2105739 Chemical compound OC(=O)\C=C/C(O)=O.C1C[C@@H](CS(=O)(=O)NC)CC[C@@H]1N(C)C1=NC=NC2=C1C=CN2 VQIGDTLRBSNOBV-VQIYXBGXSA-N 0.000 description 8
230000001419 dependent effect Effects 0.000 description 8
-1 N-methyl-1-{trans-4-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexyl}methanesulfonate Chemical compound 0.000 description 7
102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 7
102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 7
230000000873 masking effect Effects 0.000 description 7
238000011287 therapeutic dose Methods 0.000 description 7
206010020751 Hypersensitivity Diseases 0.000 description 6
230000007815 allergy Effects 0.000 description 6
239000002775 capsule Substances 0.000 description 6
230000008482 dysregulation Effects 0.000 description 6
210000000987 immune system Anatomy 0.000 description 6
238000005192 partition Methods 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
102000003951 Erythropoietin Human genes 0.000 description 5
108090000394 Erythropoietin Proteins 0.000 description 5
101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 5
102000013462 Interleukin-12 Human genes 0.000 description 5
108010065805 Interleukin-12 Proteins 0.000 description 5
108010000837 Janus Kinase 1 Proteins 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 5
208000026935 allergic disease Diseases 0.000 description 5
102000003675 cytokine receptors Human genes 0.000 description 5
108010057085 cytokine receptors Proteins 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
229940105423 erythropoietin Drugs 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
230000036470 plasma concentration Effects 0.000 description 5
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 5
239000003826 tablet Substances 0.000 description 5
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
102000013264 Interleukin-23 Human genes 0.000 description 4
108010065637 Interleukin-23 Proteins 0.000 description 4
102000042838 JAK family Human genes 0.000 description 4
108091082332 JAK family Proteins 0.000 description 4
206010035664 Pneumonia Diseases 0.000 description 4
239000007894 caplet Substances 0.000 description 4
230000004064 dysfunction Effects 0.000 description 4
244000144972 livestock Species 0.000 description 4
230000011664 signaling Effects 0.000 description 4
231100001274 therapeutic index Toxicity 0.000 description 4
208000035143 Bacterial infection Diseases 0.000 description 3
102000015696 Interleukins Human genes 0.000 description 3
108010063738 Interleukins Proteins 0.000 description 3
125000000217 alkyl group Chemical group 0.000 description 3
208000022362 bacterial infectious disease Diseases 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
230000007774 longterm Effects 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
201000002266 mite infestation Diseases 0.000 description 3
230000003285 pharmacodynamic effect Effects 0.000 description 3
238000011321 prophylaxis Methods 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
210000003491 skin Anatomy 0.000 description 3
206010040882 skin lesion Diseases 0.000 description 3
231100000444 skin lesion Toxicity 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
208000024827 Alzheimer disease Diseases 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
241001128004 Demodex Species 0.000 description 2
208000020693 Demodicidosis Diseases 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
241000283086 Equidae Species 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
208000004262 Food Hypersensitivity Diseases 0.000 description 2
206010016946 Food allergy Diseases 0.000 description 2
101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 2
102000003816 Interleukin-13 Human genes 0.000 description 2
108090000176 Interleukin-13 Proteins 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
102000000588 Interleukin-2 Human genes 0.000 description 2
108090001005 Interleukin-6 Proteins 0.000 description 2
102000004889 Interleukin-6 Human genes 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
102000001253 Protein Kinase Human genes 0.000 description 2
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
206010040844 Skin exfoliation Diseases 0.000 description 2
102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 2
230000002411 adverse Effects 0.000 description 2
230000000172 allergic effect Effects 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
230000006399 behavior Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
238000013461 design Methods 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
235000013305 food Nutrition 0.000 description 2
235000020932 food allergy Nutrition 0.000 description 2
230000036449 good health Effects 0.000 description 2
230000003394 haemopoietic effect Effects 0.000 description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
230000006872 improvement Effects 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
229940047122 interleukins Drugs 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000007726 management method Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
239000002674 ointment Substances 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000035699 permeability Effects 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
108060006633 protein kinase Proteins 0.000 description 2
238000011160 research Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
238000012546 transfer Methods 0.000 description 2
229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical class OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
241000272517 Anseriformes Species 0.000 description 1
206010003399 Arthropod bite Diseases 0.000 description 1
208000012657 Atopic disease Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
241000271566 Aves Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
208000020084 Bone disease Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
AWHNMJLNYQFRRP-UMSPYCQHSA-N CN([C@@H]1CC[C@H](CC1)C)C=1C2=C(N=C(N=1)C)NC=C2 Chemical compound CN([C@@H]1CC[C@H](CC1)C)C=1C2=C(N=C(N=1)C)NC=C2 AWHNMJLNYQFRRP-UMSPYCQHSA-N 0.000 description 1
241000282465 Canis Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
208000014085 Chronic respiratory disease Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
DSLZVSRJTYRBFB-LLEIAEIESA-L D-glucarate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O DSLZVSRJTYRBFB-LLEIAEIESA-L 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
206010012442 Dermatitis contact Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
241000792859 Enema Species 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
206010017553 Furuncle Diseases 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 1
101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
102000039992 IL-3 family Human genes 0.000 description 1
108091069211 IL-3 family Proteins 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
206010061217 Infestation Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 description 1
108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 description 1
102100021596 Interleukin-31 Human genes 0.000 description 1
101710181613 Interleukin-31 Proteins 0.000 description 1
102000004388 Interleukin-4 Human genes 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
108010019437 Janus Kinase 2 Proteins 0.000 description 1
108010019421 Janus Kinase 3 Proteins 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
206010024438 Lichenification Diseases 0.000 description 1
208000008771 Lymphadenopathy Diseases 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
241000283903 Ovis aries Species 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010033733 Papule Diseases 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
241000286209 Phasianidae Species 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
206010056342 Pulmonary mass Diseases 0.000 description 1
208000006311 Pyoderma Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
206010037888 Rash pustular Diseases 0.000 description 1
241000509427 Sarcoptes scabiei Species 0.000 description 1
206010039509 Scab Diseases 0.000 description 1
102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
241000282887 Suidae Species 0.000 description 1
208000024799 Thyroid disease Diseases 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
101710112791 Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
101710112792 Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
229940022663 acetate Drugs 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
208000002029 allergic contact dermatitis Diseases 0.000 description 1
231100000360 alopecia Toxicity 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000011203 antimicrobial therapy Methods 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
229940050390 benzoate Drugs 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
150000001642 boronic acid derivatives Chemical class 0.000 description 1
239000006189 buccal tablet Substances 0.000 description 1
FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
230000009087 cell motility Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
230000001055 chewing effect Effects 0.000 description 1
235000013330 chicken meat Nutrition 0.000 description 1
210000002987 choroid plexus Anatomy 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
208000010247 contact dermatitis Diseases 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
230000035618 desquamation Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000007435 diagnostic evaluation Methods 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000000857 drug effect Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000005713 exacerbation Effects 0.000 description 1
238000004299 exfoliation Methods 0.000 description 1
239000000835 fiber Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
150000004675 formic acid derivatives Chemical class 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012458 free base Substances 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
208000003512 furunculosis Diseases 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
229940097042 glucuronate Drugs 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
108091008039 hormone receptors Proteins 0.000 description 1
208000000069 hyperpigmentation Diseases 0.000 description 1
230000003810 hyperpigmentation Effects 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
230000002584 immunomodulator Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
108040006852 interleukin-4 receptor activity proteins Proteins 0.000 description 1
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
201000003265 lymphadenitis Diseases 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
229940049920 malate Drugs 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
150000002688 maleic acid derivatives Chemical class 0.000 description 1
150000002689 maleic acids Chemical class 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
238000003032 molecular docking Methods 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
230000035772 mutation Effects 0.000 description 1
KYTZHLUVELPASH-UHFFFAOYSA-N naphthalene-1,2-dicarboxylic acid Chemical compound C1=CC=CC2=C(C(O)=O)C(C(=O)O)=CC=C21 KYTZHLUVELPASH-UHFFFAOYSA-N 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
208000003154 papilloma Diseases 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
206010034674 peritonitis Diseases 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
208000008423 pleurisy Diseases 0.000 description 1
230000003334 potential effect Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
238000012545 processing Methods 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000001823 pruritic effect Effects 0.000 description 1
208000029561 pustule Diseases 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000022983 regulation of cell cycle Effects 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
239000013037 reversible inhibitor Substances 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
238000006748 scratching Methods 0.000 description 1
230000002393 scratching effect Effects 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
239000007787 solid Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Dermatology (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)

CN201810369706.3A 2012-07-20 2013-07-18 Janus激酶（jak）抑制剂的给药方案 Pending CN108354938A (zh)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201261674289P	2012-07-20	2012-07-20
US61/674,289		2012-07-20
US201361815803P	2013-04-25	2013-04-25
US61/815,803		2013-04-25
CN201380038563.3A CN104470525A (zh)	2012-07-20	2013-07-18	Janus激酶(jak)抑制剂的给药方案

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CN201380038563.3A Division CN104470525A (zh)	2012-07-20	2013-07-18	Janus激酶(jak)抑制剂的给药方案

Publications (1)

Publication Number	Publication Date
CN108354938A true CN108354938A (zh)	2018-08-03

Family

ID=48901189

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CN201810369706.3A Pending CN108354938A (zh)	2012-07-20	2013-07-18	Janus激酶（jak）抑制剂的给药方案
CN201380038563.3A Pending CN104470525A (zh)	2012-07-20	2013-07-18	Janus激酶(jak)抑制剂的给药方案

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CN201380038563.3A Pending CN104470525A (zh)	2012-07-20	2013-07-18	Janus激酶(jak)抑制剂的给药方案

Country Status (25)

Country	Link
US (1)	US9522151B2 (2)
EP (1)	EP2874630B1 (2)
JP (2)	JP6022063B2 (2)
KR (2)	KR20170034949A (2)
CN (2)	CN108354938A (2)
AU (1)	AU2013292547B2 (2)
BR (1)	BR112015000808A2 (2)
CA (1)	CA2878867C (2)
CY (1)	CY1121436T1 (2)
DK (1)	DK2874630T3 (2)
ES (1)	ES2707627T3 (2)
HK (2)	HK1209314A1 (2)
HR (1)	HRP20182088T1 (2)
HU (1)	HUE042771T2 (2)
IN (1)	IN2015DN00370A (2)
LT (1)	LT2874630T (2)
MX (1)	MX360857B (2)
NZ (1)	NZ703152A (2)
PL (1)	PL2874630T3 (2)
PT (1)	PT2874630T (2)
RS (1)	RS58242B1 (2)
SI (1)	SI2874630T1 (2)
SM (1)	SMT201900044T1 (2)
WO (1)	WO2014015107A1 (2)
ZA (1)	ZA201500134B (2)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GEP201606600B (en)	2013-02-22	2017-01-10	Pfizer	Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak)
WO2016024185A1 (en)	2014-08-12	2016-02-18	Pfizer Inc.	Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
US12365689B2 (en)	2015-10-16	2025-07-22	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en)	2015-10-16	2023-10-03	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913990RA (en)	2015-10-16	2020-03-30	Abbvie Inc	PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11365198B2 (en)	2015-10-16	2022-06-21	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en)	2015-10-16	2020-02-04	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10973913B2 (en)	2016-02-16	2021-04-13	Washington University	JAK inhibitors and uses thereof
CN107098908B (zh) *	2016-02-23	2021-01-08	欣凯医药科技(上海)有限公司	一种吡咯并嘧啶类化合物的制备方法和应用
KR102195348B1 (ko)	2018-11-15	2020-12-24	에이치케이이노엔 주식회사	단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
MX2021008984A (es) *	2019-01-30	2021-09-08	Felicamed Biotechnology Co Ltd	Inhibidor jak y metodo de preparacion del mismo.
US11992490B2 (en)	2019-10-16	2024-05-28	Incyte Corporation	Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
MX2023007150A (es)	2020-12-18	2023-09-04	Boehringer Ingelheim Animal Health Usa Inc	Compuestos de pirazol que contienen boro, composiciones que los comprenden, métodos y usos de los mismos.
AU2022239128B2 (en) *	2021-03-16	2024-09-05	Hk Inno.N Corporation	Novel salts of heterocyclic compound as protein kinase inhibitor and uses thereof
CA3216017A1 (en) *	2021-04-22	2022-10-27	Shengjian Huang	Pharmaceutical composition containing jak3/jak1/tbk1 selective inhibitor and medical use thereof
WO2024259429A2 (en) *	2023-06-16	2024-12-19	The University Of Chicago	Methods and compositions for pharmaceutically relevant interactions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010020905A1 (en) *	2008-08-20	2010-02-25	Pfizer Inc.	Pyrrolo[2,3-d]pyrimidine compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SK286640B6 (sk)	1998-06-19	2009-03-05	Pfizer Products Inc.	Pyrol [2,3-d] pyrimidínová zlúčenina, jej použitie na výrobu liečiva, farmaceutická kompozícia s jej obsahom, použitie jej kombinácie s ďalšími činidlami a súpravy s jej obsahom na výrobu liečiva

2013
- 2013-07-18 CN CN201810369706.3A patent/CN108354938A/zh active Pending
- 2013-07-18 DK DK13742573.2T patent/DK2874630T3/en active
- 2013-07-18 SM SM20190044T patent/SMT201900044T1/it unknown
- 2013-07-18 SI SI201331328T patent/SI2874630T1/sl unknown
- 2013-07-18 JP JP2015523243A patent/JP6022063B2/ja active Active
- 2013-07-18 MX MX2015000871A patent/MX360857B/es active IP Right Grant
- 2013-07-18 US US14/415,047 patent/US9522151B2/en active Active
- 2013-07-18 AU AU2013292547A patent/AU2013292547B2/en active Active
- 2013-07-18 PT PT13742573T patent/PT2874630T/pt unknown
- 2013-07-18 HU HUE13742573A patent/HUE042771T2/hu unknown
- 2013-07-18 KR KR1020177007913A patent/KR20170034949A/ko not_active Ceased
- 2013-07-18 NZ NZ703152A patent/NZ703152A/en unknown
- 2013-07-18 WO PCT/US2013/051015 patent/WO2014015107A1/en not_active Ceased
- 2013-07-18 ES ES13742573T patent/ES2707627T3/es active Active
- 2013-07-18 BR BR112015000808A patent/BR112015000808A2/pt not_active Application Discontinuation
- 2013-07-18 CA CA2878867A patent/CA2878867C/en active Active
- 2013-07-18 LT LTEP13742573.2T patent/LT2874630T/lt unknown
- 2013-07-18 HK HK15109423.1A patent/HK1209314A1/xx unknown
- 2013-07-18 PL PL13742573T patent/PL2874630T3/pl unknown
- 2013-07-18 EP EP13742573.2A patent/EP2874630B1/en not_active Revoked
- 2013-07-18 CN CN201380038563.3A patent/CN104470525A/zh active Pending
- 2013-07-18 KR KR1020157001085A patent/KR20150028299A/ko not_active Ceased
- 2013-07-18 IN IN370DEN2015 patent/IN2015DN00370A/en unknown
- 2013-07-18 HR HRP20182088TT patent/HRP20182088T1/hr unknown
- 2013-07-18 RS RS20190051A patent/RS58242B1/sr unknown
2015
- 2015-01-08 ZA ZA2015/00134A patent/ZA201500134B/en unknown
2016
- 2016-08-05 JP JP2016154135A patent/JP2017019816A/ja active Pending
2018
- 2018-08-23 HK HK18110906.2A patent/HK1252083A1/zh unknown
2019
- 2019-02-14 CY CY20191100203T patent/CY1121436T1/el unknown

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010020905A1 (en) *	2008-08-20	2010-02-25	Pfizer Inc.	Pyrrolo[2,3-d]pyrimidine compounds

Also Published As

Publication number	Publication date
CA2878867C (en)	2018-01-09
HK1209314A1 (en)	2016-04-01
MX360857B (es)	2018-11-20
HRP20182088T1 (hr)	2019-02-08
KR20170034949A (ko)	2017-03-29
AU2013292547B2 (en)	2017-05-04
ES2707627T3 (es)	2019-04-04
PL2874630T3 (pl)	2019-04-30
CY1121436T1 (el)	2020-05-29
CA2878867A1 (en)	2014-01-23
WO2014015107A1 (en)	2014-01-23
AU2013292547A1 (en)	2015-01-22
CN104470525A (zh)	2015-03-25
NZ703152A (en)	2016-03-31
BR112015000808A2 (pt)	2017-06-27
EP2874630A1 (en)	2015-05-27
EP2874630B1 (en)	2018-12-05
JP2017019816A (ja)	2017-01-26
SI2874630T1 (sl)	2019-04-30
JP6022063B2 (ja)	2016-11-09
SMT201900044T1 (it)	2019-02-28
US9522151B2 (en)	2016-12-20
LT2874630T (lt)	2019-02-11
HK1252083A1 (zh)	2019-05-17
MX2015000871A (es)	2015-05-07
DK2874630T3 (en)	2019-01-28
HUE042771T2 (hu)	2019-07-29
RS58242B1 (sr)	2019-03-29
US20150126535A1 (en)	2015-05-07
JP2015522620A (ja)	2015-08-06
ZA201500134B (en)	2016-08-31
PT2874630T (pt)	2019-01-31
KR20150028299A (ko)	2015-03-13
IN2015DN00370A (2)	2015-06-12

Legal Events

Date	Code	Title	Description
2018-08-03	PB01	Publication
2018-08-28	SE01	Entry into force of request for substantive examination
2018-08-28	SE01	Entry into force of request for substantive examination
2019-05-17	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1252083 Country of ref document: HK

Publication	Publication Date	Title
CA2878867C (en)	2018-01-09	Dosing regimen for janus kinase (jak) inhibitors
EP4028007B1 (en)	2025-03-26	Treatment of hidradenitis suppurativa with a jak inhibitor
US20240390378A1 (en)	2024-11-28	Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
US20240075038A1 (en)	2024-03-07	Application of pyrido[1,2-a]pyrimidinone analog
EP4333840B1 (en)	2025-11-05	Jak1 pathway inhibitors for the treatment of prurigo nodularis
CN118984704A (zh)	2024-11-19	治疗卵巢癌的药物组合和方法
CN118541364A (zh)	2024-08-23	氨基吡唑化合物的用途
US20230293544A1 (en)	2023-09-21	Methods, dosage regimens, and compositions for treating hidradenitis
HK40115079A (zh)	2025-03-21	用於治疗汗腺炎的方法、剂量方案和组合物